Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SU-TESTO is a testosterone-based formulation developed by Sinovo, typically appearing in their product line as SU-TESTO 300. It functions as an androgen receptor agonist, mimicking the effects of endogenous testosterone to promote protein synthesis, muscle growth, and the maintenance of secondary sexual characteristics. The product is designed as a sustained-release injectable solution, likely containing a blend of testosterone esters (such as testosterone propionate, phenylpropionate, isocaproate, and decanoate) to provide a stable therapeutic level of the hormone over an extended period. It is primarily intended for the treatment of male hypogonadism or other conditions requiring androgen replacement therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SU-TESTO.